H-1B sponsorship profile: Akebia Therapeutics, Inc. Across U.S. Department of Labor LCA disclosures, Akebia Therapeutics, Inc filed 14 Labor Condition Applications covering 14 H-1B worker positions between fiscal year 2023 and fiscal year 2025. The employer’s DOL certification rate sits at 100% (14 certified of 14 filed), a useful proxy for how cleanly their prevailing-wage attestations pass the Labor Department’s preliminary review before USCIS adjudication.

Compensation spread. Offered wages on Akebia Therapeutics, Inc’s H-1B petitions range from $81,078 at the low end to $185,166 at the high end, with a petition-weighted average of $145,818. That range reflects the mix of occupations the company sponsors, led by Senior, Drug Safety & PV Scientist (2 petitions at $168,717 avg), followed by Senior Oracle Solution Architect and Principal Scientist (Drug Product). H-1B salaries reported on LCAs must meet or exceed the DOL prevailing wage for the role and worksite, so the spread also tracks wage-level geography and seniority.

Geographic footprint. Akebia Therapeutics, Inc is headquartered in Cambridge, MA under NAICS code 3254, and places H-1B workers across 4 states, most heavily in MA, NC, NJ. Combined, these signals give a granular view of how one employer uses the H-1B program, volume, approval cleanliness, wage posture, and where the jobs actually sit on the map.

Where Akebia Therapeutics, Inc ranks. By H-1B petition volume, Akebia Therapeutics, Inc is #13,107 of 119,880 employers nationally and #555 of 5,193 employers headquartered in MA. Both ranks are computed live from the same underlying petition counts, not a separate estimate.